Tak Yun
Overview
Explore the profile of Tak Yun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim K, Hwang S, Kim M, Park K, Yun T, Lee K, et al.
Cancer Res Treat
. 2025 Feb;
PMID: 39901702
Purpose: The TRIUMPH trial was a biomarker-driven umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This analysis focuses on the PIK3CAɑ inhibitor...
2.
Kim Y, Keam B, Joo Kang E, Kim J, Kim H, Lee K, et al.
Cancer Res Treat
. 2024 Apr;
56(4):1068-1076.
PMID: 38637966
Purpose: In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in...
3.
Pak C, Yoon S, Lee J, Yun T, Park I
Curr Oncol Rep
. 2024 Feb;
26(4):307-317.
PMID: 38381366
Purpose Of Review: To provide a comprehensive overview of the current understanding and developments in the treatment options for adrenocortical carcinoma (ACC), focusing on the strategies utilized for advanced disease....
4.
Kim D, Lim Y, Ock C, Park G, Park S, Song H, et al.
Head Neck
. 2023 Oct;
45(12):3086-3095.
PMID: 37828867
Background: This study analyzed the predictive value of artificial intelligence (AI)-powered tumor-infiltrating lymphocyte (TIL) analysis in recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) treated with axitinib. Methods: Patients from...
5.
Keam B, Hong M, Shin S, Heo S, Kim J, Ahn H, et al.
J Clin Oncol
. 2023 Sep;
42(5):507-517.
PMID: 37699162
Purpose: A precise oncologic approach for head and neck squamous cell carcinoma (HNSCC) is necessary. We performed a genomic profile-based umbrella trial for the patients with platinum-refractory recurrent and/or metastatic...
6.
Hanna G, Ahn M, Muzaffar J, Keam B, Bowles D, Wong D, et al.
Clin Cancer Res
. 2023 Aug;
29(22):4555-4563.
PMID: 37643133
Purpose: This open-label, single-arm, phase II study evaluated the vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) rivoceranib in patients with recurrent or metastatic (R/M) adenoid cystic...
7.
Choi W, Lee Y, Choi B, Park B, Kim Y, Yun T, et al.
Cytotherapy
. 2023 Aug;
25(11):1236-1241.
PMID: 37632518
Background Aims: Human telomerase reverse transcriptase (hTERT) is an attractive target for anti-cancer therapies. We developed an effective method for generating hTERT-specific CD8 T cells (hTERT-induced natural T cells [TERTiNTs])...
8.
Jung H, Park K, Cho S, Lim J, Lee K, Hong M, et al.
Clin Cancer Res
. 2022 Jul;
28(19):4240-4247.
PMID: 35819451
Purpose: Although programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors are promising agents for recurrent or metastatic nasopharyngeal carcinoma (NPC), PD-1/PD-L1 inhibitor monotherapy has shown modest efficacy. This study evaluated...
9.
Joo Kang E, Ahn M, Ock C, Lee K, Kwon J, Yang Y, et al.
Clin Cancer Res
. 2021 Jul;
27(19):5272-5279.
PMID: 34315722
Purpose: The role of chemotherapy in adenoid cystic carcinoma (ACC) is controversial because ACC is usually stable without chemotherapy and the lack of randomized trials. Here, we conducted the first...
10.
Lee J, Jung M, Kim J, Kim B, Kim Y, Kim Y, et al.
Cancer Res Treat
. 2021 Mar;
53(2):323-329.
PMID: 33721486
At the end of 2019, the cause of pneumonia outbreaks in Wuhan, China, was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In February 2020, the World Health...